Compile Data Set for Download or QSAR
Report error Found 273 Enz. Inhib. hit(s) with all data for entry = 9986
TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404343(US10343992, Example 2 | US10689345, Example 2 | US...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404344(US10343992, Example 3 | US10689345, Example 3 | US...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404349(3-(3-chlorophenyl)-N-(1- cyanopyrrolidin-3-yl)isox...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404354(3'-chloro-N-(1-cyanopyrrolidin-3- yl)-[1,1'-biphen...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404355(N-(1-cyanopyrrolidin-3-yl)-2'- methoxy-[1,1'-biphe...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404382((R)-N-(1-cyanopyrrolidin-3-yl)- [1,1'-biphenyl]-4-...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404383((R)-6-(4-chlorophenyl)-N-(1- cyanopyrrolidin-3-yl)...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404384((R)-2-(2-chlorophenyl)-N-(1- cyanopyrrolidin-3-yl)...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404385((R)-4-(3-chloropyridin-4-yl)-N- (1-cyanopyrrolidin...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404386((R)-4-(3-chloropyridin-4-yl)-N- (1-cyanopyrrolidin...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404387((R)-N-(1-cyanopyrrolidin-3-yl)-3- methoxy-4-(2-met...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404392((R)-N-(1-cyanopyrrolidin-3-yl)-4- (1-methyl-1H-pyr...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM504675(rac-(3aR,6aR)-1-([1,1'-biphenyl]- 3-carbonyl)hexah...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404418(US10343992, Example 70 | US10689345, Example 70 | ...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404420(US10343992, Example 72 | US10689345, Example 72 | ...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404424((R)-N-(1-cyanopyrrolidin-3-yl)-3- fluoro-4-(1-meth...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404425((R)-N-(1-cyanopyrrolidin-3-yl)-2- fluoro-4-(1-meth...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404426((R)-N-(1-cyanopyrrolidin-3-yl)- 2,5-difluoro-4-(1-...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404427((R)-N-(1-cyanopyrrolidin-3-yl)-4- (1,3-dimethyl-1H...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404428((R)-N-(1-cyanopyrrolidin-3-yl)-4- (1,3-dimethyl-1H...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404429((R)-N-(1-cyanopyrrolidin-3-yl)-4- (1-ethyl-1H-pyra...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404433((R)-N-(1-cyanopyrrolidin-3-yl)-2- fluoro-4-(5-(tri...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404434((R)-N-(1-cyanopyrrolidin-3-yl)-2- fluoro-4-(1-meth...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404438((3aR,6aR)-5-cyano-N-(2-fluoro-4-(trifluoromethyl)p...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404439(US10343992, Example 91 | US10689345, Example 91 | ...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404441(2-(2-chlorophenyl)-N-((trans)-1-cyano-4-hydroxypyr...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM447556((R)-N-(1-cyanopyrrolidin- 3-yl)-5-(4-methoxyphenyl...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404445((R)-N-(1-cyanopyrrolidin- 3-yl)-5-(2-methoxyphenyl...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404446((R)-N-(1-cyanopyrrolidin- 3-yl)-5-(2-fluorophenyl)...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404448((R)-N-(1-cyanopyrrolidin- 3-yl)-3-(4- methoxypheny...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM505430((R)-N-(1- cyanopyrrolidin- 3-yl)-5-phenyl- 1H-pyra...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404453((R)-N-(1-cyanopyrrolidin- 3-yl)-2-fluoro-4-(2- met...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404460((R)-N-(1-cyanopyrrolidin- 3-yl)-3,5-difluoro-4-(1-...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM505444((R)-6-(3- cyanophenyl)- N-(1- cyanopyrrolidin- 3-y...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404466((R)-N-(1-cyanopyrrolidin- 3-yl)-2-fluoro-4- (imida...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404467((R)-N-(1-cyanopyrrolidin- 3-yl)-2-fluoro-4-(2- mor...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404468((R)-N-(1-cyanopyrrolidin- 3-yl)-3-fluoro-5-(1-meth...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404469((R)-N-(1-cyanopyrrolidin- 3-yl)-3-fluoro-5-(1-meth...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404471((R)-3-chloro-N-(1- cyanopyrrolidin-3-yl)-5-(4- flu...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404474((R)-N-(1-cyanopyrrolidin- 3-yl)-5-(1-methyl-1H- py...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404476((R)-N-(1- cyanopyrrolidin- 3-yl)-6-(3,5- dimethyli...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404477((R)-N-(1- cyanopyrrolidin- 3-yl)-6-(1,3-dimethyl- ...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404478((R)-N-(1-cyanopyrrolidin- 3-yl)-5-(1-methyl-1H- py...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM447592((R)-N-(1-cyanopyrrolidin- 3-yl)-2,3-difluoro-4-(1-...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404490((R)-N-(1-cyanopyrrolidin- 3-yl)-3-fluoro-4- (pyrim...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404491((R)-N-(1-cyanopyrrolidin- 3-yl)-2-fluoro-4-(pyrrol...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404493((R)-N-(1-cyanopyrrolidin- 3-yl)-2,5-difluoro-4- (p...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404497((R)-N-(1-cyanopyrrolidin- 3-yl)-2-fluoro-4-((4- me...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404502((R)-N-(1-cyanopyrrolidin-3-yl)-6-(3, 5-dimethyliso...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM404503((R)-N-(1-cyanopyrrolidin-3-yl)-1-(cyclopropylmethy...)
Affinity DataIC50: 100nMAssay Description:USP30 biochemical fluorescence intensity IC50 assay Dilution plates were prepared at 21 times the final concentration (2100 μM for a final conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/23/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 273 total ) | Next | Last >>
Jump to: